Table 3 Outcomes for PFS and QA PFS in an alternative scenario with UK utilities (mean number of months and 95% CrI)
| Â | Pac/Carb | Gem/Cis | Pem/Cis | Gefitinib |
|---|---|---|---|---|
PFS (months) | 6.7 (6.0; 7.4) | 7.0 (6.1; 7.9) | 7.2 (6.2; 8.2) | 10.5 (8.9; 12.4) |
QALY associated with duration of PFS (months) | 4.4 (3.9; 4.8) | 4.6 (4.0; 5.2) | 4.7 (4.0; 5.4) | 6.9 (5.8; 8.1) |
QALY increment associated with objective response in PFS | 0.17 (0.13; 0.20) | 0.19 (0.15; 0.24) | 0.22 (0.17; 0.28) | 0.39 (0.31; 0.49) |
QALY adjustment due mode of administration | −0.16 (−0.16; -0.15) | −0.16 (−0.17; -0.15) | −0.16 (−0.17; -0.15) | −0.15 (−0.17; -0.12) |
QALY decrement associated with adverse events in PFS | −0.051 (−0.055; -0.047) | −0.054 (−0.063; -0.045) | −0.060 (−0.076; -0.046) | −0.006 (−0.004; -0.007) |
Total QA-PFS (months) | 4.3 (3.8; 4.8) | 4.5 (3.9; 5.2) | 4.7 (4.0; 5.4) | 7.1 (6.0; 8.4) |
ΔQA-PFS with gefitinib (months) | 2.8 (1.9; 3.9) | 2.6 (1.6; 3.7) | 2.4 (1.4; 3.6) | - |